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Objective: To investigate the relation between biochemical markers of bone, cartilage, and synovial
remodelling and the structural progression of knee osteoarthritis.
Methods: 62 patients of both sexes with knee osteoarthritis were followed prospectively for one year. From
magnetic resonance imaging (MRI), done at baseline and after one year, the volume and thickness of
cartilage of the femur, the medial tibia, and the lateral tibia were assessed. A whole organ magnetic
resonance imaging score (WORMS) of the knee was calculated for each patient at baseline and at the one
year visits. This score consists in a validated, semiquantitative scoring system for whole organ assessment
of the knee in osteoarthritis using MRI. Biochemical markers (serum hyaluronic acid, osteocalcin, cartilage
glycoprotein 39 (YKL-40), cartilage oligomeric matrix protein (COMP), and C-telopeptide of type I
collagen (CTX-I), and urine C-telopeptide of type II collagen (CTX-II)) were measured at baseline and after
three months.
Results: Baseline markers were not correlated with one year changes observed in cartilage volume and
thickness. However, an increase in CTX-II after three months was significantly correlated with a one year
decrease in mean thickness of medial tibial and lateral tibial cartilage. Patients in the highest quartile of
three month changes in CTX-II experienced a mean loss of 0.07 (0.08) mm of their medial thickness,
compared with a mean increase of 0.05 (0.19) mm for patients in the lowest quartile (p = 0.04) Multiple
regression analysis showed that high baseline levels of hyaluronic acid are predictive of a worsening in
WORMS (p = 0.004).
Conclusions: These results suggest that a single measurement of serum hyaluronic acid or short term
changes in urine CTX-II could identify patients at greatest risk of progression of osteoarthritis.
O
steoarthritis of the knee joint is a progressive disorder
often leading to permanent disability.1 Traditionally,
physical examination and plain radiographs have
been relied upon in diagnosis, treatment selection, and
research studies. However, these assessments do not provide
a reliable tool for identifying patients who will experience a
rapid progression of the disease (that is, in whom earlier
intervention may be indicated).2 Prospective clinical studies
of new treatment options in osteoarthritis are lengthy and
cumbersome owing to lack of sensitive methods for
investigating disease progression and difficulties in the
patient selection process. There is an urgent need for reliable,
sensitive, and specific tools capable of promptly assessing the
progression of this disease.3
Radiography is acknowledged to be the best validated
method for assessing joint damage in osteoarthritis.4 It allows
the measurement of changes in joint space width (JSW),
which currently remains the gold standard for evaluating the
use of structure modifying drugs in osteoarthritis.5 However,
JSW measurement does not allow the detection of early
structural damage nor is it an efficient way of monitoring the
progression of osteoarthritis in daily practice.4 Magnetic
resonance imaging (MRI), with its superior soft tissue
contrast, is the ideal technique for assessing normal articular
cartilage and cartilage lesions. Joint imaging has the
potential of providing morphological information, such as
the presence of fissuring, partial or full thickness cartilage
defects, and signal changes within residual cartilage.5
Moreover, MRI, with its ability to discriminate articular
tissues, holds the greatest potential as a tool for whole organ
imaging of the joint. An MRI global knee joint score has
recently been validated.6
The metabolic alterations in joint tissues associated with
osteoarthritis involve changes in both the synthesis and
degradation of matrix molecules, which are then often
released as fragments into joint fluid, blood, and urine where
they may be detected.7 Markers that reflect the ongoing
repair and degenerative processes occurring within a joint
might be regarded as tools capable of predicting the rate of
osteoarthritis progression. Biochemical markers have been
shown to complement imaging techniques as surrogate
markers of disease progression in a variety of diseases such
as osteoporosis and rheumatoid arthritis.4 In osteoarthritis,
several biochemical markers of bone, cartilage, and synovium
turnover have been reported to be potentially useful in
identifying patients at high risk of rapid joint degradation.3
However, the ability of different biochemical markers to
detect early changes occurring in osteoarthritis and thereby
to serve as prognostic tools for future cartilage alterations has
not been exhaustively tested.3–5
This paper describes our investigation into the value of
undertaking a single (at baseline) or repeated measurements
(at three month intervals) of bone, cartilage, and synovial
turnover markers for determining the severity of osteoar-
thritis and predicting long term (12 month) progression of
knee osteoarthritis, as assessed by MRI.
Abbreviations: COMP, cartilage oligomeric matrix protein; FOV, field




 on 13 July 2009 ard.bmj.comDownloaded from 
METHODS
Patients
The cohort consisted in 62 patients (49 women) with medial
compartment primary knee osteoarthritis. They were part of a
non-intervention, prospective, study of 12 months’ duration.
They were enrolled if knee osteoarthritis was diagnosed at
screening by the radiographic Kellgren-Lawrence grading
scale for knee osteoarthritis.8 All patients were classified as
grade 2 or grade 3 at baseline. Osteoarthritis at other sites
besides the knee was permissible. The main exclusion criteria
were history or active presence of other rheumatic diseases
that could be responsible for secondary osteoarthritis,
medical or surgical treatment on the knee within the previous
six months, weight exceeding 114 kg (250 lb), and any MRI
contraindications. Patients had no known cancer or liver
disease. We have also excluded from this study patients who
had had intra-articular injections of steroids, in any joints,
within the previous 30 days or more than three injections in
the previous six months, as well as those having intra-
articular injections of hyaluronic acid within the previous
90 days. During the study, no patient received intra-articular
steroid injections or glucosamine treatment. However, during
follow up, patients could have treatment with non-steroidal
anti-inflammatory drugs for symptom relief.
MRI acquisit ion
MRI of the study knee of each patient was acquired with a 1.5
Tesla whole body scanner, using a commercial circumfer-
ential knee coil. Imaging sequences were as follows:
N axial T1 weighted spin echo: time of repetition (TR) in ms/
time of echo (TE) in ms, 700/11; 20 cm field of view
(FOV); slice thickness/interslice gap, 5 mm/1 mm;
2566192 matrix, frequency encoding (FE) anterior-poster-
ior, one excitation;
N coronal T1 weighted spin echo: 600/11, 16 cm FOV, 4 mm/
0.5 mm, 2566192, FE superior-inferior, two excitations
averaged;
N sagittal T1 weighted spin echo: 600/11, 16 cm FOV, 4 mm/
0.5 mm, 256692, FE anterior-posterior, two excitations
averaged;
N sagittal T2 weighted fast spin echo: 2500/90; echo train
length = 8; 14 cm FOV, 4 mm/0 mm, 2566192, FE super-
ior-inferior, two excitations averaged, with fat suppression
(frequently selective presaturation);
N sagittal fat suppressed T1 weighted, three dimensional,
spoiled gradient echo (FS-3DSPGR): 58/6, 40˚ flip angle,
14 cm FOV, 2566128 matrix, 60 contiguous 2 mm slices
covering all articular cartilage plates in the knee, FE,
superior-inferior, one excitation, frequency selective fat
saturation, and superior-inferior saturation bands to
minimise pulsation artefacts.
The total time required for MRI, including patient set up,
was 60 minutes. All images were visually inspected for
quality. In case of poor quality, repeat images were acquired
within a window of 10 days.
Volume and thickness assessment
Cartilage volume and thickness of the femur, the medial
tibia, and the lateral tibia were assessed using three
dimensional image processing. The cartilage was measured
using a semiautomated region growing approach that has
been presented and validated previously. In this technique,
trained readers mark seed points within the cartilage and
draw boundaries between low contrast regions of concurrent
cartilage plates; the region growing technique then delineates
the entire cartilage. Cartilage volumes were read in a paired
fashion, but blinded to visit sequence.9
Whole organ MRI scoring (WORMS)
All images were transferred to a Sun Workstation and
analysed using MRVision software (MRVision Inc, Menlo
Park, California, USA) and were scored by validated readers.
Images were scored with respect to 14 independent articular
features: cartilage signal and morphology, subarticular bone
marrow abnormality, subarticular cysts, subarticular bone
attrition, marginal osteophytes, medial and lateral meniscal
integrity, anterior and posterior cruciate ligament integrity,
medial and lateral collateral ligament integrity, synovitis,
loose bodies, and periarticular cysts or bursae. Two muscu-
loskeletal radiologists undertook the readings independently.
The final WORMS scores were tabulated as: (a) independent
values for each feature in each of the three compartments of
the knee (patello-femoral joint; medial femoro-tibial joint;
lateral femoro-tibial joint); (b) cumulative surface feature
scores (cartilage, marrow abnormality, subarticular cysts,
bone attrition, osteophytes) for each compartment; (c)
cumulative scores for each feature throughout the knee;
and (d) a total combined score for the entire knee.6 One
reader read the entire set of images. The images were read
paired, with the visit sequence being blinded. Before reading,
the readers were trained by Dr Charles Peterfy. The reader
showed excellent reproducibility, as described in a previous
paper.6
Measurement of biochemical markers
Urine and blood collection were taken at baseline and after
three months of follow up. Venous blood was sampled after
an overnight fast and urine was collected on the second
morning void. Blood was collected from the most visible vein
near the elbow of the non-dominant arm (unless this was
contraindicated), at least one hour after rising. Patients were
not admitted to hospital. The time interval between blood
sample collection and centrifugation for serum preparation
was within two hours. The samples were stored at 280 C˚.
The analyses were done within three months after storage.
Serum hyaluronic acid
Serum hyaluronic acid was measured by an enzyme linked
binding protein assay, the ‘‘Hyaluronic Acid (HA) Test’’
(Corgenix Inc, Westminster, Colorado, USA), using hyaluro-
nic acid binding protein isolated from bovine cartilage. The
limit of detection of the method was 10 ng/ml. The within
and between assay coefficients of variation were less than
10%.
Serum osteocalcin
Serum osteocalcin was measured by an immunoradiometric
assay (IRMA), ‘‘OSTEO-RIACT’’ (CIS bio International, Gif-
sur-Yvette, France), using two monoclonal antibodies raised
against two sterically remote sites of the intact molecule. The
limit of detection of the method was 0.4 ng/ml. The within
and between assay coefficients of variation were less than
10%.
Serum intact or fragmented carti lage oligomeric
matrix protein
Serum intact or fragmented cartilage oligomeric matrix
protein (COMP) was measured by inhibition enzyme linked
immunosorbent assay, ‘‘WielisaH hCOMP’’ (Wieslab, Lund,
Sweden), using a rabbit polyclonal antiserum directed to
human COMP. The limit of detection of the method was
estimated at 500 ng/ml. The within and between assay
coefficients of variation were less than 11%.
Serum carti lage glycoprotein 39
Serum cartilage glycoprotein 39 (YKL-40) was measured
using a sandwich enzyme immunoassay, ‘‘MetraTM YKL-40
Osteoarthritis, MRI, and biochemical markers 1051
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EIA’’ (Quidel Co, San Diego, California, USA), employing a
Fab fragment of a mouse monoclonal anti-human YKL-40
antibody as catcher and a rabbit polyclonal anti-human YKL-
40 antibody for detection. The limit of detection of the
method was estimated at 20 ng/ml. The within and between
assay coefficients of variation were less than 10%.
Serum C-telopeptides of type I collagen
Serum C-telopeptides of type I collagen (CTX-I) was
measured with an enzyme linked immunosorbent assay,
‘‘Serum CrossLapsH ELISA’’ (Nordic Bioscience Diagnostics
A/S, Herlev, Denmark). This assay uses two monoclonal
antibodies directed against a b-isomerised form of an eight
amino acid sequence (EKAHD-bGGR) of the C-telopeptide of
the a1 chain of type I collagen. The limit of detection of the
method was estimated at 125 pM. The within and between
assay coefficients of variation were less than 16%.
Urine C-telopeptides of type II collagen
Urine C-telopeptides of type II collagen (CTX-II) was
measured with an enzyme linked immunosorbent assay,
‘‘u-CartiLapsH ELISA’’ (Nordic Bioscience Diagnostics). The
assay uses a monoclonal antibody (MAbF46) highly specific
for a six amino acid epitope (EKGPDP) derived from C-
telopeptide of type II collagen. The limit of detection of the
method was estimated at 0.17 mg/l. The within and between
assay coefficients of variation were less than 12%. The assay
values were corrected for urinary dilution by urine creatinine
levels and finally expressed in mg/mmol creatinine. Urine
creatinine was measured with the Jaffe´ method on a
‘‘Modular’’ auto-analyser (Roche Diagnostics GmbH,
Mannheim, Germany).
Statistical analysis
Quantitative variables at baseline were expressed as mean
(SD) and qualitative as frequencies. Because the biomarkers
levels were not normally distributed, they were log trans-
formed before analysis. Relations between biochemical
markers and clinical or radiological severity of knee
osteoarthritis were assessed by the calculation of
Spearman’s correlation coefficients, by a multiple regression
analysis and by a stepwise regression analysis. The results
were considered significant at the 5% level (p,0.05). No
adjustment for multiple comparisons was made to the type I
error rate, as the analysis was exploratory in nature.
Statistical calculations were carried out with the Stastistica
software.
RESULTS
The cohort included 62 patients (46 women), with a mean
(SD) age of 64.9 (10.3) years and a mean body mass index of
28.1 (4.7) kg/m2. Of these patients, 28 (45%) were classified
as grade 2 by the Kellgren-Lawrence grading scale, and 34
(55%) as grade 3. MRI assessment of the knees showed a
lateral tibial volume of 1742 (528) ml, a medial tibial volume
of 1301 (337) ml, a femur volume of 6316 (1231) ml, a lateral
tibial thickness of 1.83 (0.35) mm, a medial tibial thickness
of 1.52 (0.22) mm, a femur thickness of 1.17 (0.15) mm, and
a WORMS of 43.8 (34.9). Biochemical markers rates of the
population are summarised in tables 1 and 2.
Baseline markers were not correlated with one year
changes observed in cartilage volume and thickness. In
particular, we did not find any significant associations
between CTX-II rate and cartilage changes (r values between
0.03 and 0.19 and p values between 0.16 and 0.87). However,
an increase in CTX-II after three months was significantly
correlated with a one year decrease in mean thickness of
medial tibial (r =20.30, p = 0.03) and lateral tibial cartilage
(r =20.38, p = 0.005). After adjusting for age, sex, and body
mass index with multiple regression analysis, three month
increases in CTX-II were significantly predictive of one year
loss in thickness of the medial (p = 0.03) and lateral
(p = 0.001) tibial cartilage. Patients within the highest
quartile of three month changes in CTX-II (.0.056 mg/mmol)
experienced a mean loss of 0.07 (0.08) mm of their medial
thickness compared with a mean increase of 0.05 (0.19) mm
for patients within the lowest quartile (,20.055 mg/mmol)
(p = 0.04 between the two groups) (fig 1). In patients with a
decrease in the medial tibial cartilage thickness, CTX-II
values did not change after three months (+0.01 (0.11))
compared with a small decrease of 20.11 (0.43) in patients
with an increase of the medial tibial cartilage thickness
(p = 0.19 between the two groups).
Baseline levels of COMP and CTX-II were correlated with
baseline WORMS (p = 0.03 and p = 0.0002, respectively).
These results remain significant after multiple regression
analysis. Baseline hyaluronic acid was not significantly
associated with baseline WORMS (p = 0.06). However,
multiple regression analysis showed a strong positive
association between the one year variation in the WORMS
and the baseline sample of hyaluronic acid (p = 0.004). This
indicates that high levels of hyaluronic acid are predictive of
worsening osteoarthritis as assessed by MRI.
Table 1 Baseline biochemical marker levels
Variable Median (range)
Serum hyaluronic acid (ng/ml) 69 (16 to 293)
Serum osteocalcin (ng/ml) 12.3 (5.4 to 39.3)
Serum COMP (ng/ml) 1627 (912 to 2755)
Serum YKL-40 (ng/ml) 82 (25 to 221)
Serum CTX-I (pM) 3030 (1035 to 8873)
Urine CTX-II (mg/mmol creatinine) 0.26 (0.07 to 0.89)
COMP, cartilage oligomeric matrix protein; CTX-I, C-telopeptides of type
I collagen; CTX-II, C-telopeptides of type II collagen; YKL-40, cartilage
glycoprotein 39.
Table 2 Three month biochemical marker levels
Variable Median (range)
Serum hyaluronic acid (ng/ml) 68 (19 to 293)
Serum osteocalcin (ng/ml) 12.6 (5.2 to 31.3)
Serum COMP (ng/ml) 1711 (931 to 2784)
Serum YKL-40 (ng/ml) 77 (24 to 439)
Serum CTX-I (pM) 3112 (997 to 9688)
Urine CTX-II (mg/mmol creatinine) 0.27 (0.09 to 0.85)
COMP, cartilage oligomeric matrix protein; CTX-I, C-telopeptides of type
I collagen; CTX-II, C-telopeptides of type II collagen; YKL-40, cartilage
glycoprotein 39.
Figure 1 One year changes in
medial tibia cartilage thickness
stratified for quartiles of three
month changes in CTX-II level.
CTX-II, C-telopeptides of type II
collagen.
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DISCUSSION
Using a panel of biochemical indices of bone, cartilage, and
synovial tissue turnover, we found that a single measurement
of serum hyaluronic acid or short term changes in urine CTX-
II could identify the patients at greatest risk of osteoarthritis
progression.
Biochemical markers of bone, cartilage, or synovial
remodelling have the potential to serve as diagnostic tools
for osteoarthritis. Increases in serum or urine levels of
COMP,10–12 hyaluronic acid,10 13 14 and CTX-II10 15–17 have been
described previously in osteoarthritis patients compared with
controls. On the other hand, very few studies have assessed
the relation between the structural severity of osteoarthritis
and biochemical markers.13 15 16 18 In this study, we showed
no significant correlation at baseline between the level of any
of the various biochemical markers and any single MRI
feature (volume and thickness of cartilage of the medial tibia,
the lateral tibia and the femur). However, when using a
validated global MRI score, a significant association was
found between damage severity score and two biochemical
markers (COMP and CTX-II, p = 0.03 and p = 0.0002,
respectively). To the best of our knowledge, the only other
study using MRI assessment of joint damage showed that
YKL-40, measured in synovial fluid, correlated with synovial
membrane and the joint effusion volumes determined by
MRI.19 Using standard x ray, we previously reported the
absence of significant associations, at baseline, between
biochemical markers (serum keratan sulphate, serum hya-
luronic acid, urine pyridinoline and deoxypyridinoline, serum
osteocalcin, and COMP) and femoro-tibial joint space width
in more than 200 patients with knee osteoarthritis.18 Garnero
et al reported that an increased CTX-II and glucosyl-galactosyl
pyridinoline levels were significantly correlated with cartilage
loss.10 However, no significant associations were reported
between joint space width and other biochemical markers
(COMP, CTX-I, YKL-40, hyaluronic acid, and C reactive
protein).10 Obviously, joint space narrowing on standard
x rays only produces an indirect assessment of cartilage
damage. However, pathologically, osteoarthritis is an episo-
dical inflammatory disorder of synovial joints characterised
by the focal deterioration and abrasion of articular cartilage,
with sclerosis and cyst formation in the underlying bone, as
well as the formation of osteophytes at the joint surface.20
Thickening of the joint capsule and chronic synovitis are also
commonly reported features. In this study, we showed a
significant association between global joint damage severity
score and CTX-II and COMP levels. Our results corroborate
the hypothesis that, because hyaluronic acid and COMP are
not cartilage specific and because these biochemical markers
levels were not correlated with knee cartilage volume or
thickness, the pathogenesis of osteoarthritis not only involves
cartilage but also bone and synovium.21–23 Our results
obtained with COMP and hyaluronic acid may suggest that
synovial inflammation plays a central role in the pathogen-
esis of osteoarthritis. The key role of inflammation in
osteoarthritis is supported by histological evidence of severe
inflammation, raised levels of biomarkers related to synovitis,
and heightened levels of pro-inflammatory cytokine expres-
sion in osteoarthritic chondrocytes. Moreover, MRI and
ultrasonography have demonstrated synovitis in early
osteoarthritis.
Another field of interest for biochemical markers is the
identification of patients at increased risk of rapid disease
progression. Some studies found a predictive value of
hyaluronic acid,13 24 C reactive protein,25 COMP,26 27 bone
sialoprotein,26 osteocalcin,18 procollagen of type II collagen
(PIINP),28 CTX II,15–17 Coll 2-1,29 and Coll 2-1 NO2
29 for
radiographic progression. To the best of our knowledge, our
study is the first to assess the value of biochemical markers
for predicting the progression of osteoarthritis using MRI. We
found that a single measurement of serum hyaluronic acid
could predict a one year progression of the validated whole-
organ MRI score of the knee in patients with osteoarthritis.
Our results are in accordance with previous reports of the
predictive value of hyaluronic acid13 24 for joint space
narrowing, assessed on x rays. Recently, Pavelka et al reported
that osteoarthritis patients with high basic serum level of
hyaluronic acid had a rapid radiological progression (r = 0.30,
p,0.005).13 In our study, we used a validated global joint
score to assess structural severity. WORMS combines
individual scores for articular cartilage, osteophytes, bone
marrow abnormality, subchondral cysts, and bone attrition in
14 locations. It also incorporates scores for the medial and
lateral menisci, anterior and posterior cruciate ligaments,
medial and lateral collateral ligaments, and synovial disten-
sion.6 Our results suggest that hyaluronic acid level predicts
global damage in patient with knee osteoarthritis, and not
only cartilage loss. This seems reasonable because, as a major
product of synovial cells, hyaluronic acid is considered to be a
marker of synovial inflammation4 and so is not cartilage
specific. This study suggests that short term changes in CTX-
II identify patients at greatest risk of losing tibial cartilage
after one year. These results are in accordance with our
previous report that, when using x ray to assess joint damage
severity, 12 month changes in CTX-II correlated with the
changes in joint space width (on x ray assessment) observed
after 36 months (r = 0.43, p,0.05).16 Garnero et al reported
that an increased level of U-CTX-II was correlated with the
one year progression of knee joint damage in 67 patients with
knee osteoarthritis (though the significance was borderline:
r =20.27, p = 0.056).15 A recent study showed that, in an
osteoarthritis cohort of 1235 men and women followed for a
mean of 6.6 year, subjects with CTX-II levels in the highest
quartile had a sixfold increased risk for progression of
radiographic osteoarthritis in the knee.20 It should be noted
that the correlation coefficients were low (0.32 and 0.38) and
account for little of the variance of cartilage lost. However,
the association between biological markers and cartilage
volume were stronger when the analysis was adjusted for
age, sex, and body mass index, suggesting that the variance
accounts for more than is apparent. It should also be noted
that the importance of changes in thickness of less than
1 mm is not yet established. Several large ongoing studies
such as the Osteoarthritis Initiative will be able to address
this question. Our study, however, does clearly show a
significant association between CTX-II and thickness loss. We
must also acknowledge that the matrix of acquisition for the
cartilage volume sequences might not be adequate to pick up
small changes in volume. However, other studies have shown
important results using a similar matrix size. In our present
study, the size was chosen to minimise the time taken for the
investigation, and thereby patient discomfort.
Conclusion
These results suggest that a single measurement of serum
hyaluronic acid or short term changes in urine CTX-II may
identify patients at greatest risk of osteoarthritis progression.
This could be helpful for the clinician in identifying patients
who should be treated with a structure modifying drug rather
than with simple analgesics.
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